125 related articles for article (PubMed ID: 32198428)
1. Assessing the impact of AGS-004, a dendritic cell-based immunotherapy, and vorinostat on persistent HIV-1 Infection.
Gay CL; Kuruc JD; Falcinelli SD; Warren JA; Reifeis SA; Kirchherr JL; James KS; Dewey MG; Helms A; Allard B; Stuelke E; Gamble A; Plachco A; Gorelick RJ; Eron JJ; Hudgens M; Garrido C; Goonetilleke N; DeBenedette MA; Tcherepanova IY; Nicolette CA; Archin NM; Margolis DM
Sci Rep; 2020 Mar; 10(1):5134. PubMed ID: 32198428
[TBL] [Abstract][Full Text] [Related]
2. Cellular Gene Modulation of HIV-Infected CD4 T Cells in Response to Serial Treatment with the Histone Deacetylase Inhibitor Vorinostat.
Maxwell JW; Falcinelli SD; Nefedov A; Dorfmeier C; Wu G; Dewey M; Webber AL; Archin NM; Margolis DM; Hazuda DJ; Barnard RJO; Howell BJ
J Virol; 2020 Jun; 94(13):. PubMed ID: 32295913
[TBL] [Abstract][Full Text] [Related]
3. Interval dosing with the HDAC inhibitor vorinostat effectively reverses HIV latency.
Archin NM; Kirchherr JL; Sung JA; Clutton G; Sholtis K; Xu Y; Allard B; Stuelke E; Kashuba AD; Kuruc JD; Eron J; Gay CL; Goonetilleke N; Margolis DM
J Clin Invest; 2017 Aug; 127(8):3126-3135. PubMed ID: 28714868
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity of AGS-004 Dendritic Cell Therapy in Patients Treated During Acute HIV Infection.
Gay CL; DeBenedette MA; Tcherepanova IY; Gamble A; Lewis WE; Cope AB; Kuruc JD; McGee KS; Kearney MF; Coffin JM; Archin NM; Hicks CB; Eron JJ; Nicolette CA; Margolis DM
AIDS Res Hum Retroviruses; 2018 Jan; 34(1):111-122. PubMed ID: 28636433
[TBL] [Abstract][Full Text] [Related]
5. The Effects of Human Immunodeficiency Virus Type 1 (HIV-1) Antigen-Expanded Specific T-Cell Therapy and Vorinostat on Persistent HIV-1 Infection in People With HIV on Antiretroviral Therapy.
Gay CL; Hanley PJ; Falcinelli SD; Kuruc JD; Pedersen SM; Kirchherr J; Raines SLM; Motta CM; Lazarski C; Chansky P; Tanna J; Shibli A; Datar A; McCann CD; Sili U; Ke R; Eron JJ; Archin N; Goonetilleke N; Bollard CM; Margolis DM
J Infect Dis; 2024 Mar; 229(3):743-752. PubMed ID: 38349333
[TBL] [Abstract][Full Text] [Related]
6. HIV-1 expression within resting CD4+ T cells after multiple doses of vorinostat.
Archin NM; Bateson R; Tripathy MK; Crooks AM; Yang KH; Dahl NP; Kearney MF; Anderson EM; Coffin JM; Strain MC; Richman DD; Robertson KR; Kashuba AD; Bosch RJ; Hazuda DJ; Kuruc JD; Eron JJ; Margolis DM
J Infect Dis; 2014 Sep; 210(5):728-35. PubMed ID: 24620025
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-15-Stimulated Natural Killer Cells Clear HIV-1-Infected Cells following Latency Reversal
Garrido C; Abad-Fernandez M; Tuyishime M; Pollara JJ; Ferrari G; Soriano-Sarabia N; Margolis DM
J Virol; 2018 Jun; 92(12):. PubMed ID: 29593039
[TBL] [Abstract][Full Text] [Related]
8. Impact of Tamoxifen on Vorinostat-Induced Human Immunodeficiency Virus Expression in Women on Antiretroviral Therapy: AIDS Clinical Trials Group A5366, The MOXIE Trial.
Scully EP; Aga E; Tsibris A; Archin N; Starr K; Ma Q; Morse GD; Squires KE; Howell BJ; Wu G; Hosey L; Sieg SF; Ehui L; Giguel F; Coxen K; Dobrowolski C; Gandhi M; Deeks S; Chomont N; Connick E; Godfrey C; Karn J; Kuritzkes DR; Bosch RJ; Gandhi RT
Clin Infect Dis; 2022 Oct; 75(8):1389-1396. PubMed ID: 35176755
[TBL] [Abstract][Full Text] [Related]
9. Stable Latent HIV Infection and Low-level Viremia Despite Treatment With the Broadly Neutralizing Antibody VRC07-523LS and the Latency Reversal Agent Vorinostat.
Gay CL; James KS; Tuyishime M; Falcinelli SD; Joseph SB; Moeser MJ; Allard B; Kirchherr JL; Clohosey M; Raines SLM; Montefiori DC; Shen X; Gorelick RJ; Gama L; McDermott AB; Koup RA; Mascola JR; Floris-Moore M; Kuruc JD; Ferrari G; Eron JJ; Archin NM; Margolis DM
J Infect Dis; 2022 Mar; 225(5):856-861. PubMed ID: 34562096
[TBL] [Abstract][Full Text] [Related]
10. Innate Immune Activity Correlates with CD4 T Cell-Associated HIV-1 DNA Decline during Latency-Reversing Treatment with Panobinostat.
Olesen R; Vigano S; Rasmussen TA; Søgaard OS; Ouyang Z; Buzon M; Bashirova A; Carrington M; Palmer S; Brinkmann CR; Yu XG; Østergaard L; Tolstrup M; Lichterfeld M
J Virol; 2015 Oct; 89(20):10176-89. PubMed ID: 26223643
[TBL] [Abstract][Full Text] [Related]
11. Dendritic Cell Immunotherapy for HIV-1 Infection Using Autologous HIV-1 RNA: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
Jacobson JM; Routy JP; Welles S; DeBenedette M; Tcherepanova I; Angel JB; Asmuth DM; Stein DK; Baril JG; McKellar M; Margolis DM; Trottier B; Wood K; Nicolette C
J Acquir Immune Defic Syndr; 2016 May; 72(1):31-8. PubMed ID: 26751016
[TBL] [Abstract][Full Text] [Related]
12. Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy.
Elliott JH; Wightman F; Solomon A; Ghneim K; Ahlers J; Cameron MJ; Smith MZ; Spelman T; McMahon J; Velayudham P; Brown G; Roney J; Watson J; Prince MH; Hoy JF; Chomont N; Fromentin R; Procopio FA; Zeidan J; Palmer S; Odevall L; Johnstone RW; Martin BP; Sinclair E; Deeks SG; Hazuda DJ; Cameron PU; Sékaly RP; Lewin SR
PLoS Pathog; 2014 Oct; 10(10):e1004473. PubMed ID: 25393648
[TBL] [Abstract][Full Text] [Related]
13. In-vivo administration of histone deacetylase inhibitors does not impair natural killer cell function in HIV+ individuals.
Garrido C; Tolstrup M; Søgaard OS; Rasmussen TA; Allard B; Soriano-Sarabia N; Archin NM; Margolis DM
AIDS; 2019 Mar; 33(4):605-613. PubMed ID: 30830886
[TBL] [Abstract][Full Text] [Related]
14. Safety and Preliminary Efficacy of Vorinostat With R-EPOCH in High-risk HIV-associated Non-Hodgkin's Lymphoma (AMC-075).
Ramos JC; Sparano JA; Rudek MA; Moore PC; Cesarman E; Reid EG; Henry D; Ratner L; Aboulafia D; Lee JY; Ambinder RF; Mitsuyasu R; Noy A
Clin Lymphoma Myeloma Leuk; 2018 Mar; 18(3):180-190.e2. PubMed ID: 29426719
[TBL] [Abstract][Full Text] [Related]
15. Effective Cytotoxic T Lymphocyte Targeting of Persistent HIV-1 during Antiretroviral Therapy Requires Priming of Naive CD8+ T Cells.
Smith KN; Mailliard RB; Piazza PA; Fischer W; Korber BT; Fecek RJ; Ratner D; Gupta P; Mullins JI; Rinaldo CR
mBio; 2016 May; 7(3):. PubMed ID: 27247230
[TBL] [Abstract][Full Text] [Related]
16. Short Communication: The Broad-Spectrum Histone Deacetylase Inhibitors Vorinostat and Panobinostat Activate Latent HIV in CD4(+) T Cells In Part Through Phosphorylation of the T-Loop of the CDK9 Subunit of P-TEFb.
Jamaluddin MS; Hu PW; Jan Y; Siwak EB; Rice AP
AIDS Res Hum Retroviruses; 2016 Feb; 32(2):169-73. PubMed ID: 26727990
[TBL] [Abstract][Full Text] [Related]
17. Type 1-programmed dendritic cells drive antigen-specific latency reversal and immune elimination of persistent HIV-1.
Kristoff J; Palma ML; Garcia-Bates TM; Shen C; Sluis-Cremer N; Gupta P; Rinaldo CR; Mailliard RB
EBioMedicine; 2019 May; 43():295-306. PubMed ID: 30952614
[TBL] [Abstract][Full Text] [Related]
18. H3K27 Demethylation at the Proviral Promoter Sensitizes Latent HIV to the Effects of Vorinostat in Ex Vivo Cultures of Resting CD4+ T Cells.
Tripathy MK; McManamy ME; Burch BD; Archin NM; Margolis DM
J Virol; 2015 Aug; 89(16):8392-405. PubMed ID: 26041287
[TBL] [Abstract][Full Text] [Related]
19. Combined effect of Vacc-4x, recombinant human granulocyte macrophage colony-stimulating factor vaccination, and romidepsin on the HIV-1 reservoir (REDUC): a single-arm, phase 1B/2A trial.
Leth S; Schleimann MH; Nissen SK; Højen JF; Olesen R; Graversen ME; Jørgensen S; Kjær AS; Denton PW; Mørk A; Sommerfelt MA; Krogsgaard K; Østergaard L; Rasmussen TA; Tolstrup M; Søgaard OS
Lancet HIV; 2016 Oct; 3(10):e463-72. PubMed ID: 27658863
[TBL] [Abstract][Full Text] [Related]
20. HIV-1 Reservoir Dynamics after Vaccination and Antiretroviral Therapy Interruption Are Associated with Dendritic Cell Vaccine-Induced T Cell Responses.
Andrés C; Plana M; Guardo AC; Alvarez-Fernández C; Climent N; Gallart T; León A; Clotet B; Autran B; Chomont N; Gatell JM; Sánchez-Palomino S; García F
J Virol; 2015 Sep; 89(18):9189-99. PubMed ID: 26109727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
